More is known about the details of TLS for the major adduct of N-2-acetylaminofluorene (AAFC8-dG), and N2-dG adducts in E. coli than for any other adducts/lesions in any other model system. In these cases, multiple translesion DNAPs are involved in both the nonmutagenic and mutagenic pathways, as outlined in this section.
AAF was originally developed as a potential pesticide, but it was abandoned when it was found to be a potent rat carcinogen [
118]. Following activation, AAF principally binds at C8-dG, as do most aromatic amine mutagens/carcinogens, where AAF and AAF-C8-dG have frequently been used as models to probe the mutagenic and carcinogenic mechanisms of aromatic amines [
117]. In
E. coli AAF has a major mutational hot spot in 5′-CG
1CG
2 sequences in which it induces −2 frameshift mutations [
117]. AAF-C8-dG at G
2 (but not G
1) causes a −2 frameshift mutation in a DNAP II-dependent process, or causes no mutation in a DNAP V-dependent process [
117]. The current model is that AAF-C8-dG at a replication fork exists in two different conformations [
66,
117]. In one conformation, the adducted dG moiety is in a −2 slipped intermediate, which DNAP II uses for insertion, and then in the presence of
β-clamp an additional three extension steps (to L + 3) are accomplished, at which point replication can be successfully continued by DNAP III [
66]. From a nonslipped intermediate, DNAP V inserts dCTP opposite AAF-C8-dG and then extends by adding four more dNTPs (to L + 4), after which DNAP III can successfully continue replication [
66]. These two pathways are followed approximately equally in cells, though by manipulating the concentration of DNAP II versus DNAP IV, the ratio [−2 frameshift

:

no mutation] can be modulated, suggesting that the two conformations interconvert [
93]. In vitro in 5′-CG
1CG
2 sequences DNAP II also does TLS to give a bypass product that should ultimately yield a −1 frameshift mutation, which are not, however, observed in vivo; recent in vitro studies suggest that DNAP II cannot extend far enough from the −1 frameshift intermediate, and, thus, the 3′ → 5′ exonuclease activity of DNAP III degrades the intermediates in the −1 frameshift pathway [
66].
Molecular modeling has provided insights about how lesion bypass might occur; for example, a modest alteration in sugar pucker (from C3′-endo to C1′-exo) is required before AAF-C8-dG can Watson-Crick base pair with dCTP [
94,
119]. Though this work was done in Dpo4 and hDNAP
ι, there is every reason to think that a similar conclusion would be reached for DNAP V. Recently, X-ray structures of the corresponding deacetylated adduct AF-C8-dG has been reported [
32]. Regrettably, the structures do not reveal insights about how dCTP might be inserted opposite AF-C8-dG, but they do offer a glimpse of more-or-less normal Watson-Crick AF-C8-dG

:

dC base pairing in the L + 1, which has the AF moiety in the opening on the major groove side of Dpo4, and in the L + 2 position, in which the AF-moiety is accommodated by a modest rearrangement in the little finger domain.
Benzo[a]pyrene (B[a]P) is a well-studied DNA damaging agent that is a potent mutagen/carcinogen and an example of a polycyclic aromatic hydrocarbon (PAH), a class of ubiquitous environmental substances produced by incomplete combustion [
120,
121]. PAHs in general and B[a]P in particular induce the kinds of mutations thought to be relevant to carcinogenesis and may be important in human cancer [
122–
128]. B[a]P mutational spectra were established with the major metabolite that reacts with DNA (i.e., (+)-
anti-B[a]PDE), in
E. coli [
129], yeast [
130,
131] and mammalian (CHO) cells [
132]. Mutagenesis has also been studied with [+ta]-B[a]P-N
2-dG (+BP, ), the major adduct of (+)-
anti-B[a]PDE, and G → T mutations predominate in most cases (see [
133] and references therein).
DNAPs IV and V of
E. coli are both involved in TLS with B[a]P-N
2-dG adducts, although they play very different roles. In studies with purified proteins, DNAP IV inserted dCTP (>99%) opposite both +BP and its mirror image −BP ([-ta]-B[a]P-N
2-dG) in a 5′-C
GA sequence, while DNAP V inserted dATP (>99%) [
77]. This tendency is evident in
E. coli. DNAP IV is required in the nonmutagenic pathway with +BP [
72–
75], −BP [
75] and other N
2-dG adducts [
72,
76]. An amino acid change (F12I) at the conserved “steric gate” (which excludes rNTPs) decreases dCTP insertion in vitro opposite several N
2-dG adducts and similarly decreases TLS in vivo, which argues that DNAP IV does dCTP insertion in vivo [
72]. In the nonmutagenic pathway DNAP V is required in addition to DNAP IV with +BP [
73–
75]. Why are two DNAPs required for nonmutagenic TLS with +BP: certain lesions need one DNAP for insertion and a second for extension [
134,
135]. Thus, if DNAP IV does dCTP insertion [
72–
77], then DNAP V must do extension, which is sensible given kinetic findings with purified proteins show that DNAP V can be significantly better than DNAP IV at the step directly following adduct-G

:

C formation (i.e., extension) in the case of +BP compared to −BP (discussed in greater detail in reference [
75]). Regarding the nonmutagenic pathway with −BP, only DNAP IV is required for efficient TLS [
75], suggesting it does both insertion and extension. In a 5′-T
GT sequence, DNAP V is required in the G → T pathway for +BP, while DNAPs II and IV are not, implying that DNAP V must do insertion and extension [
57]. However, in a 5′-G
GA sequence, G → T mutations were shown not dependent on DNAP V and were not enhanced by SOS induction, which implies no lesion-bypass DNAP involvement and led the authors to propose that DNAP III was involved in dATP insertion opposite +BP [
73,
74]. Random mutagenesis studies with [+
anti]-B[a]PDE also showed the existence of a non-SOS-inducible G → T pathway (discussed in [
57]), though the major G → T pathway did require SOS-induction, implying involvement of a lesion-bypass DNAP.